Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome

M. J. Lechowicz, H. M. Lazarus, J. Carreras, G. G. Laport, C. S. Cutler, P. H. Wiernik, G. A. Hale, D. Maharaj, R. P. Gale, P. A. Rowlings, C. O. Freytes, A. M. Miller, Julie Marie Vose, R. T. Maziarz, S. Montoto, D. G. Maloney, P. N. Hari

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

We describe outcomes after allogeneic hematopoietic cell transplantation (HCT) for mycosis fungoides and Sezary syndrome (MF/SS). Outcomes of 129 subjects with MF/SS reported to the Center for the International Blood and Marrow Transplant from 2000-2009. Median time from diagnosis to transplant was 30 (4-206) months and most subjects were with multiply relapsed/ refractory disease. The majority (64%) received non-myeloablative conditioning (NST) or reduced intensity conditioning (RIC). NST/RIC recipients were older in age compared with myeloablative recipients (median age 51 vs 44 years, P=0.005) and transplanted in recent years. Non-relapse mortality (NRM) at 1 and 5 years was 19% (95% confidence interval (CI) 12-27%) and 22% (95% CI 15-31%), respectively. Risk of disease progression was 50% (95% CI 41-60%) at 1 year and 61% (95% CI 50-71%) at 5 years. PFS at 1 and 5 years was 31% (95% CI 22-40%) and 17% (95% CI 9-26%), respectively. OS at 1 and 5 years was 54% (95% CI 45-63%) and 32% (95% CI 22-44%), respectively. Allogeneic HCT in MF/SS results in 5-year survival in approximately one-third of patients and of those, half remain disease-free.

Original languageEnglish (US)
Pages (from-to)1360-1365
Number of pages6
JournalBone marrow transplantation
Volume49
Issue number11
DOIs
StatePublished - Nov 13 2014

Fingerprint

Sezary Syndrome
Mycosis Fungoides
Cell Transplantation
Confidence Intervals
Transplants
Disease Progression
Bone Marrow
Survival
Mortality

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Lechowicz, M. J., Lazarus, H. M., Carreras, J., Laport, G. G., Cutler, C. S., Wiernik, P. H., ... Hari, P. N. (2014). Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. Bone marrow transplantation, 49(11), 1360-1365. https://doi.org/10.1038/bmt.2014.161

Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. / Lechowicz, M. J.; Lazarus, H. M.; Carreras, J.; Laport, G. G.; Cutler, C. S.; Wiernik, P. H.; Hale, G. A.; Maharaj, D.; Gale, R. P.; Rowlings, P. A.; Freytes, C. O.; Miller, A. M.; Vose, Julie Marie; Maziarz, R. T.; Montoto, S.; Maloney, D. G.; Hari, P. N.

In: Bone marrow transplantation, Vol. 49, No. 11, 13.11.2014, p. 1360-1365.

Research output: Contribution to journalArticle

Lechowicz, MJ, Lazarus, HM, Carreras, J, Laport, GG, Cutler, CS, Wiernik, PH, Hale, GA, Maharaj, D, Gale, RP, Rowlings, PA, Freytes, CO, Miller, AM, Vose, JM, Maziarz, RT, Montoto, S, Maloney, DG & Hari, PN 2014, 'Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome', Bone marrow transplantation, vol. 49, no. 11, pp. 1360-1365. https://doi.org/10.1038/bmt.2014.161
Lechowicz MJ, Lazarus HM, Carreras J, Laport GG, Cutler CS, Wiernik PH et al. Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. Bone marrow transplantation. 2014 Nov 13;49(11):1360-1365. https://doi.org/10.1038/bmt.2014.161
Lechowicz, M. J. ; Lazarus, H. M. ; Carreras, J. ; Laport, G. G. ; Cutler, C. S. ; Wiernik, P. H. ; Hale, G. A. ; Maharaj, D. ; Gale, R. P. ; Rowlings, P. A. ; Freytes, C. O. ; Miller, A. M. ; Vose, Julie Marie ; Maziarz, R. T. ; Montoto, S. ; Maloney, D. G. ; Hari, P. N. / Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. In: Bone marrow transplantation. 2014 ; Vol. 49, No. 11. pp. 1360-1365.
@article{c9239f587e964c78b4869c443a38401d,
title = "Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome",
abstract = "We describe outcomes after allogeneic hematopoietic cell transplantation (HCT) for mycosis fungoides and Sezary syndrome (MF/SS). Outcomes of 129 subjects with MF/SS reported to the Center for the International Blood and Marrow Transplant from 2000-2009. Median time from diagnosis to transplant was 30 (4-206) months and most subjects were with multiply relapsed/ refractory disease. The majority (64{\%}) received non-myeloablative conditioning (NST) or reduced intensity conditioning (RIC). NST/RIC recipients were older in age compared with myeloablative recipients (median age 51 vs 44 years, P=0.005) and transplanted in recent years. Non-relapse mortality (NRM) at 1 and 5 years was 19{\%} (95{\%} confidence interval (CI) 12-27{\%}) and 22{\%} (95{\%} CI 15-31{\%}), respectively. Risk of disease progression was 50{\%} (95{\%} CI 41-60{\%}) at 1 year and 61{\%} (95{\%} CI 50-71{\%}) at 5 years. PFS at 1 and 5 years was 31{\%} (95{\%} CI 22-40{\%}) and 17{\%} (95{\%} CI 9-26{\%}), respectively. OS at 1 and 5 years was 54{\%} (95{\%} CI 45-63{\%}) and 32{\%} (95{\%} CI 22-44{\%}), respectively. Allogeneic HCT in MF/SS results in 5-year survival in approximately one-third of patients and of those, half remain disease-free.",
author = "Lechowicz, {M. J.} and Lazarus, {H. M.} and J. Carreras and Laport, {G. G.} and Cutler, {C. S.} and Wiernik, {P. H.} and Hale, {G. A.} and D. Maharaj and Gale, {R. P.} and Rowlings, {P. A.} and Freytes, {C. O.} and Miller, {A. M.} and Vose, {Julie Marie} and Maziarz, {R. T.} and S. Montoto and Maloney, {D. G.} and Hari, {P. N.}",
year = "2014",
month = "11",
day = "13",
doi = "10.1038/bmt.2014.161",
language = "English (US)",
volume = "49",
pages = "1360--1365",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome

AU - Lechowicz, M. J.

AU - Lazarus, H. M.

AU - Carreras, J.

AU - Laport, G. G.

AU - Cutler, C. S.

AU - Wiernik, P. H.

AU - Hale, G. A.

AU - Maharaj, D.

AU - Gale, R. P.

AU - Rowlings, P. A.

AU - Freytes, C. O.

AU - Miller, A. M.

AU - Vose, Julie Marie

AU - Maziarz, R. T.

AU - Montoto, S.

AU - Maloney, D. G.

AU - Hari, P. N.

PY - 2014/11/13

Y1 - 2014/11/13

N2 - We describe outcomes after allogeneic hematopoietic cell transplantation (HCT) for mycosis fungoides and Sezary syndrome (MF/SS). Outcomes of 129 subjects with MF/SS reported to the Center for the International Blood and Marrow Transplant from 2000-2009. Median time from diagnosis to transplant was 30 (4-206) months and most subjects were with multiply relapsed/ refractory disease. The majority (64%) received non-myeloablative conditioning (NST) or reduced intensity conditioning (RIC). NST/RIC recipients were older in age compared with myeloablative recipients (median age 51 vs 44 years, P=0.005) and transplanted in recent years. Non-relapse mortality (NRM) at 1 and 5 years was 19% (95% confidence interval (CI) 12-27%) and 22% (95% CI 15-31%), respectively. Risk of disease progression was 50% (95% CI 41-60%) at 1 year and 61% (95% CI 50-71%) at 5 years. PFS at 1 and 5 years was 31% (95% CI 22-40%) and 17% (95% CI 9-26%), respectively. OS at 1 and 5 years was 54% (95% CI 45-63%) and 32% (95% CI 22-44%), respectively. Allogeneic HCT in MF/SS results in 5-year survival in approximately one-third of patients and of those, half remain disease-free.

AB - We describe outcomes after allogeneic hematopoietic cell transplantation (HCT) for mycosis fungoides and Sezary syndrome (MF/SS). Outcomes of 129 subjects with MF/SS reported to the Center for the International Blood and Marrow Transplant from 2000-2009. Median time from diagnosis to transplant was 30 (4-206) months and most subjects were with multiply relapsed/ refractory disease. The majority (64%) received non-myeloablative conditioning (NST) or reduced intensity conditioning (RIC). NST/RIC recipients were older in age compared with myeloablative recipients (median age 51 vs 44 years, P=0.005) and transplanted in recent years. Non-relapse mortality (NRM) at 1 and 5 years was 19% (95% confidence interval (CI) 12-27%) and 22% (95% CI 15-31%), respectively. Risk of disease progression was 50% (95% CI 41-60%) at 1 year and 61% (95% CI 50-71%) at 5 years. PFS at 1 and 5 years was 31% (95% CI 22-40%) and 17% (95% CI 9-26%), respectively. OS at 1 and 5 years was 54% (95% CI 45-63%) and 32% (95% CI 22-44%), respectively. Allogeneic HCT in MF/SS results in 5-year survival in approximately one-third of patients and of those, half remain disease-free.

UR - http://www.scopus.com/inward/record.url?scp=84909982000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84909982000&partnerID=8YFLogxK

U2 - 10.1038/bmt.2014.161

DO - 10.1038/bmt.2014.161

M3 - Article

VL - 49

SP - 1360

EP - 1365

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 11

ER -